Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 8Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Neoplasms 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Cytokine Release Syndrome 1Colorectal Neoplasms 1Castleman Disease 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 62Dexamethasone 60Melphalan 54Peripheral Blood Stem Cell Transplantation 49Bortezomib 40Busulfan 39fludarabine phosphate 34Filgrastim 32Lenalidomide 30Thalidomide 27Tacrolimus 25Antilymphocyte Serum 23Radiotherapy 22Mycophenolic Acid 17Methotrexate 17Prednisone 15Etoposide 15sargramostim 14Cyclosporine 14fludarabine 12Methylprednisolone 11Granulocyte Colony-Stimulating Factor 11Calcium Dobesilate 11Whole-Body Irradiation 10Doxorubicin 9Carmustine 9pomalidomide 8Vincristine 8Interferon-alpha 8Cord Blood Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms, Plasma Cell × siltuximab × Clear all
NCT01531998 2015-06-19

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

M.D. Anderson Cancer Center

Phase 1/2 Completed
14 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Centocor, Inc.

Phase 2 Completed
53 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡